P
Precision BioSciences Inc (DTIL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$7.28
-0.28 (-3.77%)
Market Cap: $288.76M
Last updated: Nov 17, 2026 at 11:04 AM ET
Precision BioSciences Inc (DTIL) Valuation Multiples
Precision BioSciences (DTIL) trades at 4.4x sales and 3.9x book value. Its P/S of 4.4x is above its 5-year median of 2.3x. Its forward P/E is 11.8x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 11.8x |
| Price to sales | 4.4x |
| Price to book | 3.9x |
| PEG | N/A |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 4.4x | 2.3x | N/A |
| P/B | 3.9x | 1.8x | N/A |
Valuation History
Over the 7 year ends shown, its P/S ranged from 0.4x in 2024 to 31.5x in 2019.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $4.16 | N/A | 2.3x | 0.9x |
| 2024 | $3.81 | 1.9x | 0.4x | 0.5x |
| 2023 | $10.96 | N/A | 0.9x | 2.6x |
| 2022 | $35.74 | N/A | 4.4x | 2.2x |
| 2021 | $222.22 | N/A | 3.7x | 4.9x |
| 2020 | $250.45 | N/A | 17.9x | 9.9x |
| 2019 | $417.12 | N/A | 31.5x | 5.1x |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DTIL
What is DTIL's forward P/E ratio?
Precision BioSciences has a forward P/E ratio of 11.8x.
Is DTIL stock overvalued?
GNG's valuation label for DTIL is Overvalued.
What is DTIL's price to sales ratio?
Precision BioSciences has a price to sales ratio of 4.4x.
DTIL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors